IBA Signs Contract to Install Next Generation Compact Proton Therapy Center in Japan

Global Interest Continues to Grow in IBA’s Compact Single-Room PT Solution Proteus®ONE

Louvain-la-Neuve, Belgium, 22 April, 2014 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today that it has signed a contract with a significant upfront payment, for the installation of its new compact single-room proton therapy system Proteus®ONE* in Japan. The completion of the order is subject to obtaining the necessary market authorizations. The financial details and the identity of the contractor are not disclosed. It is expected that the center will treat its first patient in 2017.

Olivier Legrain, Chief Executive Officer of IBA commented: “Winning this contract in Japan’s highly competitive market reconfirms IBA’s leading position in proton therapy solutions and demonstrates the growing demand for our compact system in Asia. Making proton therapy more accessible is a key strategic goal for IBA and our Proteus®ONE is making this possible. Today’s announcement is a further endorsement of the attractiveness of our compact offering and the solid experience and expertise of IBA engineers who are dedicated to developing the next generation of proton therapy compact solutions. We are convinced that Proteus®ONE will continue to be a key catalyst in our growth as we aim to bring this life saving treatment to more patients worldwide.”

This Proteus®ONE order, in a proton therapy market as demanding and sophisticated as Japan, proves that IBA has chosen the right compact system concept. It is clear that IBA’s unique Pencil Beam Scanning technique, which significantly improves treatment quality to the patient compared to other compact systems, gives IBA a clear advantage over its competitors.

Today, more than half of all proton therapy clinical facilities worldwide are equipped with IBA systems. This includes 16 proton therapy centers currently in operation and 11 additional centers under development. Over 25 000 patients have been treated using IBA equipment, which is more than all major competitive installations combined.

Proteus®ONE is the compact and affordable IMPT (Intensity Modulated Proton Therapy) solution from IBA. It benefits from the latest technologies of Proteus®PLUS, developed with top clinical institutions. Proteus®ONE is smaller, more affordable, easier to install, easier to operate and ultimately to finance, making this advanced radiotherapy modality available to more institutions worldwide. Proteus®ONE makes proton therapy accessible for more patients worldwide.

- ENDS -
Notes to Editors

About Proton Therapy
Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior
dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a
precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses
can be delivered to the tumor without increasing the risk of side effects and long-term complications,
thereby improving patient outcomes and quality of life.

*Proteus® ONE is the brand name of a new configuration of the Proteus® 235, including some new
developments subject to review by Competent Authorities (FDA, European Notified Bodies, PMDA et al.) before
marketing.

About IBA
IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the
worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy
available today.

The Company’s primary expertise lies in the development of next generation proton therapy
technologies that provide oncology care providers with premium quality services and equipment.
IBA’s proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy
centers as well as next generation compact, single room solutions. IBA also focuses on the
development and supply of dosimetry solutions for Quality Assurance of medical equipment and
increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing about 1000 people worldwide, IBA currently has installed
systems across Europe and the US and is expanding into emerging markets. The Company is
focused on building sustainable global growth for investors, providing solutions in the fight against
cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and
Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For further information please contact:

IBA
Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
thomas.ralet@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications
Amber Bielecka, Mary-Jane Elliott, Matthew Neal, Jessica Hodgson, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com